Investment Rating - The report assigns a "Buy" rating to the company with a target price of HKD 21.9, representing a potential upside of 62.2% from the current price of HKD 13.52 [2][5]. Core Insights - The company is experiencing a resurgence, driven by its innovative drug pipeline, particularly the GLP-1/GIP/GCG tri-receptor agonist UBT251, which has shown promising clinical results and secured a partnership with Novo Nordisk [5][39]. - The company has a strong position in the antibiotic market, with a comprehensive supply chain and a stable market share, despite short-term fluctuations in raw material prices [5][20]. - The insulin segment is expanding, with the company successfully participating in national procurement and increasing its market share through competitive pricing strategies [5][44][47]. Financial Summary - Revenue projections for the fiscal years ending December 31 are as follows: 2023A: CNY 13.74 billion, 2024A: CNY 13.76 billion, 2025E: CNY 14.40 billion, 2026E: CNY 13.00 billion, and 2027E: CNY 13.39 billion, with a notable increase in net profit expected in 2025 [3][5]. - The earnings per share (EPS) is projected to be CNY 1.49 for 2023, decreasing slightly to CNY 1.46 in 2024, and then increasing to CNY 1.68 in 2025 [3][5]. - The company’s price-to-earnings (P/E) ratio is estimated at 8.4 for 2023, decreasing to 7.5 in 2025, indicating a favorable valuation [3][5]. Business Analysis - The company operates across three main segments: intermediates, active pharmaceutical ingredients (APIs), and formulations, with intermediates contributing 19.3% to sales and 67.4% to profits in 2024 [18]. - The antibiotic segment remains a key revenue driver, with a market share of 45% in 6-APA and 14% in penicillin G potassium, solidifying the company's leading position [34]. - The insulin and GLP-1 segments are poised for growth, with the company actively participating in national procurement and expanding its product offerings to meet rising demand [39][48]. R&D and Innovation - The company has over 100 products in the research pipeline, focusing on diabetes, weight management, and other metabolic diseases, supported by a robust R&D infrastructure [12][48]. - The partnership with Novo Nordisk for UBT251 is expected to accelerate clinical development and commercialization, enhancing the company's innovative drug portfolio [5][39]. - The company is also developing GLP-1 biosimilars, positioning itself to capitalize on the growing market for these products as patents expire [51][52].

Investment Rating - The report maintains a "Buy" rating for Tencent Music [4] Core Views - The online music revenue is expected to increase due to the growth in paid users and ARPPU, leading to an overall improvement in profit margins. The forecasted net profit for the years 2025-2027 is 10.41 billion, 10.14 billion, and 11.16 billion RMB respectively, with a target price of 94.86 HKD [2][4] Financial Performance Summary - The company's revenue for 2023 is projected at 27,752 million RMB, with a year-on-year growth of -2.1%. This is expected to rise to 31,453 million RMB in 2025, reflecting a growth of 10.7% [3][9] - Operating profit is forecasted to increase significantly from 4,777 million RMB in 2023 to 9,440 million RMB in 2025, showing a growth rate of 28.5% [3][9] - The net profit attributable to the parent company is expected to grow from 4,920 million RMB in 2023 to 10,411 million RMB in 2025, representing a substantial increase of 56.7% [3][9] - The gross margin is projected to improve from 35.3% in 2023 to 45.6% in 2025, indicating enhanced profitability [3][9] Revenue Breakdown - Online music revenue for Q1 is reported at 58.0 billion RMB, with a year-on-year increase of 15.9%. The forecast for Q2 is 64.3 billion RMB, reflecting an 18.6% growth [7] - Social entertainment revenue for Q1 is 15.5 billion RMB, showing a decline of 11.9% year-on-year, with expectations of continued challenges in Q2 [7] Market Position and Valuation - The target price of 94.86 HKD is based on a P/E ratio of 27 times for 2026, which is aligned with comparable companies in the industry [2][8] - The report highlights a strong performance relative to the Hang Seng Index, with a 1-week absolute performance of 13.51% and a 1-month performance of 30.05% [5]

2025 年 5 月 21 日 | 何利超 | | | --- | --- | | H70529@capital.com.tw | | | 目标价(港币) | HK$ 0.8 | 公司基本资讯 | 产业别 | | | 传媒 | | --- | --- | --- | --- | | H 股价(2025/05/20) | | | 0.61 | | 恒生指数(2025/05/20) | | | 23,681.5 | | 股价 12 个月高/低 | | | 0.63/0.35 | | 总发行股数(百万) | | | 29,875.86 | | H 股数(百万) | | | 29,875.86 | | H 市值(亿元) | | | 134.44 | | | | 阿里巴巴集团控 | | | 主要股东 | | | 股有限公司 | | | | | (53.85%) | | 每股净值(元) | | | 0.55 | | 股价/账面净值 | | | 1.12 | | 一个月 | | 三个月 | 一年 | | 股价涨跌(%) | 25.77% | -3.17% | 34.07% | 近期评等 | | | | 产品组合 | | | ...

AI 驱动广告、游戏收入持续超预期增长 ——腾讯控股（0700.HK）25Q1 季报点评 | | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入(百万元) | 609,015 | 660,257 | 741,393 | 823,081 | 911,511 | | 同比增长 (%) | 9.82% | 8.41% | 12.29% | 11.02% | 10.74% | | 营业利润(百万元) | 152,784 | 200,097 | 239,238 | 272,041 | 308,598 | | 同比增长 (%) | 52.76% | 30.97% | 19.56% | 13.71% | 13.44% | | 归属母公司净利润(百万元) | 115,216 | 194,073 | 218,491 | 248,401 | 277,831 | | 同比增长 (%) | -38.79% | 68.44% | 12.58% | 13.69% | 11.85% | | 每股收益（元） | 12.5 ...

奇富科技 (QFIN US/3660 HK) 1Q25：利润合预期，质量小幅波动 | 华泰研究 | | | 季报点评 | | --- | --- | --- | --- | | 2025 年 | 5 月 | 21 日│美国/中国香港 | 其他多元金融 | 奇富科技 1Q25 业绩：收入 46.9 亿元（环比/同比：+4.7/+12.9%），归母净 利润 18.0 亿元（环比/同比：-6.1/+54.6%）。利润基本符合我们此前 17.5 亿元的预期，处于公司指引区间 17.5-18.5 亿元的中枢。风险指标略有上升， C-M2 比率升至 0.6%（4Q24：0.57%），但仍属健康水平，低于 1Q21-4Q24 的均值 0.62%。拨备覆盖率进一步升至 666%（4Q24：617%），表明盈利 质量较高。放款量 889 亿元，环比略降 1.1%，在有春节假期的情况下能够 几乎持平，可能反映了需求略有回暖。行业内仍在评估"助贷新规"的影响， 新规将于 10 月 1 日起施行，建议持续关注。公司是行业内体量较大的平台， 或仍将采取谨慎的经营策略，预计 25 年放款量温和增长，基于高质量盈利 和较高的股东回报（截至 ...

Investment Rating - The report maintains a "Buy" rating for Tencent Music [4] Core Views - The online music revenue is expected to continue increasing due to the growth in paid users and ARPPU, leading to an overall improvement in profit margins. The forecasted net profit for the years 2025 to 2027 is 10.41 billion, 10.14 billion, and 11.16 billion RMB respectively, with a target price set at 94.86 HKD [2][4] Financial Performance Summary - The company's revenue for 2023 is projected at 27.75 billion RMB, with a year-on-year growth of -2.1%. This is expected to rise to 31.45 billion RMB in 2025, reflecting a growth of 10.7% [3][9] - Operating profit is forecasted to increase significantly from 4.78 billion RMB in 2023 to 9.44 billion RMB in 2025, marking a growth of 28.5% [3][9] - The net profit attributable to the parent company is expected to grow from 4.92 billion RMB in 2023 to 10.41 billion RMB in 2025, representing a substantial increase of 56.7% [3][9] - The gross margin is anticipated to improve from 35.3% in 2023 to 45.6% in 2025, while the net margin is expected to rise from 17.7% to 33.1% over the same period [3][9] Revenue Breakdown - Online music revenue for Q1 is reported at 5.8 billion RMB, showing a year-on-year increase of 15.9%. The forecast for Q2 is 6.43 billion RMB, with an expected growth of 18.6% [7] - Social entertainment revenue for Q1 is 1.55 billion RMB, down 11.9% year-on-year, with expectations for Q2 to remain flat [7] Market Position and Valuation - The target price of 94.86 HKD corresponds to a P/E ratio of 27 times for 2026, based on comparable company analysis [2][8] - The report highlights a strong performance relative to the Hang Seng Index, with a 1-week absolute performance of 13.51% and a 1-month performance of 30.05% [5]

2025 年 5 月 20 日，三生制药与辉瑞签订许可协议，授权辉瑞在全球（除中国外）对 707 的研发、生产和 商业化权益，本次授权的首付款为 12.5 亿美元，并可获得总额最多为 48.0 亿美元的潜在付款，包括开发、 监管批准及销售的里程碑付款，以及双位数百分比的销售分成。 国信医药观点：1）707 是三生制药研发的一款 PD-1xVEGF 双抗，研发进度较为靠前，早期临床数据优秀； 近日，707 单药头对头帕博利珠单抗针对一线 PD-L1 阳性的 NSCLC 的临床 3 期已经在 CDE 官网公示；2）707 目前单药在一线 PD-L1 阳性的 NSCLC、联合化疗在一线 NSCLC、结直肠癌、子宫内膜癌等实体瘤中开展临 床研究，其中一线 PD-L1 阳性的 NSCLC 适应症获得 CDE 突破性治疗认定，助力 707 的研发和商业化进程快 速推进；3）707 的商业化出海能力得到兑现，与辉瑞达成授权协议，协议总金额为 60.5 亿美元，其中首 付款 12.5 亿美元，里程碑付款 48.0 亿美元，以及双位数百分比的销售分成；此外，辉瑞将于生效日期根 据股份认购协议内容，认购公司 1.0 亿美元的三生 ...

证券研究报告 | 公司点评 gszqdatemark 2025 05 21 年 月 日 三生制药（01530.HK） 授权辉瑞 PD-1/VEGF 双抗，创新管线未来可期 公司发布公告：与辉瑞就 PD-1/VEGF 双抗 SSGJ-707 达成授权协议。 5 月 20 日，公司宣布，公司及附属子公司沈阳三生、三生国健与辉瑞签署 协议，将向辉瑞独家授予公司自主研发的突破性 PD-1/VEGF 双特异性抗 体 SSGJ-707 在全球（不包括中国内地）的开发、生产、商业化权利。公 司及沈阳三生将保留 SSGJ-707 在中国内地的开发、生产、商业化权利， 并基于届时商定的财务条款授予辉瑞对 SSGJ-707 在中国内地开展商业化 的选择权。根据协议，三生制药将获得 12.5 亿美元不可退还且不可抵扣 的首付款，以及最高可达 48 亿美元的开发、监管批准和销售里程碑付款。 公司还将根据授权地区的产品销售额收取两位数百分比的梯度销售分成。 此外，辉瑞将于协议生效日认购三生制药价值 1 亿美元的普通股股份。 SSGJ-707 临床效果获国际认可，财务回报助力公司研发体系升级。SSGJ- 707 是三生制药基于 CLF2 ...

证券研究报告 | 公司点评 gszqdatemark 2025 05 21 年 月 日 三生制药（01530.HK） 授权辉瑞 PD-1/VEGF 双抗，创新管线未来可期 公司发布公告：与辉瑞就 PD-1/VEGF 双抗 SSGJ-707 达成授权协议。 5 月 20 日，公司宣布，公司及附属子公司沈阳三生、三生国健与辉瑞签署 协议，将向辉瑞独家授予公司自主研发的突破性 PD-1/VEGF 双特异性抗 体 SSGJ-707 在全球（不包括中国内地）的开发、生产、商业化权利。公 司及沈阳三生将保留 SSGJ-707 在中国内地的开发、生产、商业化权利， 并基于届时商定的财务条款授予辉瑞对 SSGJ-707 在中国内地开展商业化 的选择权。根据协议，三生制药将获得 12.5 亿美元不可退还且不可抵扣 的首付款，以及最高可达 48 亿美元的开发、监管批准和销售里程碑付款。 公司还将根据授权地区的产品销售额收取两位数百分比的梯度销售分成。 此外，辉瑞将于协议生效日认购三生制药价值 1 亿美元的普通股股份。 SSGJ-707 临床效果获国际认可，财务回报助力公司研发体系升级。SSGJ- 707 是三生制药基于 CLF2 ...

制造毛利率和利润下滑系各厂区产能负载不均，新造产线及新设鞋面加工 厂爬坡不如预期，生产效率未达设定标准，无法如期降低加班需求及相关 成本；人数同增 8%+各地薪资上涨高单位数百分比导致人工成本上升。 25M4：整体营收同比+1%（1-4 月累计同比+1%），其中制造同比+11%（1-4 月累计同比+7%），宝胜营收同比-15%（1-4 月累计同比-8%），零售业务仍 在修复中。 1）制造（25Q1） 市场分布：美国收入同比+14%，占比 29%，欧洲收入同比+11%，占比 27%； 中国大陆收入同比-19%，占比 15%。欧美为营收主要贡献地区。 港股公司报告 | 公司点评 裕元集团（00551） 证券研究报告 25Q1 鞋履制造量价稳增 公司发布 25 财年一季度未经审计业绩和 25 年四月收益公告 25Q1：营收同比+1%至 20 亿美金，毛利率 23%，同比-2.2pct，归母净利同 比-24%至 0.8 亿美金。 其中制造业务营收同比+6%，毛利率 18%，同比-2.6pct，归母净利同比-25%； 零售业务营收同比-5%，毛利率 33%，同比-0.5pct，归母净利同比-21%。 库存：库存周转天数 ...